Free shipping on all orders over $ 500


Cat. No. M2104
BYL-719 Structure

Alpelisib; BYL719

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 57  USD57 In stock
2mg USD 39  USD39 In stock
5mg USD 50  USD50 In stock
10mg USD 66  USD66 In stock
50mg USD 98  USD98 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Alpelisib (Byl-719) is an effective, selective PI3Kα inhibitor with oral activity. Alpelisib (Byl-719) was targeted to PIK3CA mutated carcinoma. The IC50 of Alpelisib (Byl-719) against P110 α, P110 γ, p110δ and P110 β were 5 nM, 250 nM, 290 nM and 1200 nM, respectively. It has antitumor activity.

Product Citations
Customer Product Validations & Biological Datas
Source Int J Cancer (2015). Figure 1. BYL719
Method Caspase 3/7 activity assay
Cell Lines HOS and MOS-J cells
Concentrations 25 μM
Incubation Time 24 and 48 hr
Results After 72 hr of treatment, BYL719 significantly inhibited the cell growth of all osteosarcoma cell lines tested in a dosedependent manner with an IC50 ranging from 6 to 15 μM and with the IC90 from 24 to 42 μM at 72 hr.
Chemical Information
Molecular Weight 441.47
Formula C19H22F3N5O2S
CAS Number 1217486-61-7
Solubility (25°C) DMSO 72 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Fabrice Andr, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer

[2] Dejan Juric, et al. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

[3] Ingrid A Mayer, et al. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer

[4] Christine Fritsch, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials

[5] Pascal Furet, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Related PI3K Products

SNV4818 is a potential best-in-class (best-in-class) mutation-selective PI3K-α inhibitor with excellent selectivity for the H1047X mutant and moderate selectivity for the related E545/542X mutant.

hSMG-1 inhibitor 11j

hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM.


RLY-2608 is a first-in-class, orally active, selective inhibitor of PI3Ka metabolism.


EDI048 is an orally active Cryptosporidium PI4K inhibitor for the research of cryptosporidiosis.


PI3Kδ-IN-13 is a PI3Kδ inhibitor (IC50=2.6 nM).

Abmole Inhibitor Catalog

Keywords: BYL-719, Alpelisib; BYL719 supplier, PI3K, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.